FDA safety concerns with repeated use of gadolinium-based contrast; subjects received additional dose of contrast with no direct clinical benefit

This study will compare the use of two contrast agents to analyze blood flow characteristics of brain tumors.

This study will compare contrast agents, gadobenate dimeglumine and gadobutrol, for MRI perfusion analysis in brain tumor patients.

Inclusion Criteria:

• Subjects with brain tumors will be enrolled. These subjects may be newly diagnosed, undergoing treatment or undergoing follow-up. If a subject has undergone surgery or treatment they should have what appears to be residual tumor.

Exclusion Criteria:

• Renal failure (GFR <45). Subjects will be screened utilizing UNMC gadolinium contrast guidelines.

• Allergic reactions to MRI contrast agents.

• Subjects who do not fit the criteria for the population we are evaluating.

• Subjects should not participate in this study if they have any of the following conditions:

  • Anxiety attacks
  • Panic disorder
  • Claustrophobia
  • Pregnant, or trying to become pregnant
  • Breast feeding

• Subjects should not participate in this study if they have certain kinds of metal in their body, for example: a heart pacemaker, defibrillator, neurostimulator, a metal plate, certain otologic implants, certain types of heart valves, metal slivers in eye, brain aneurysm clips or metal slivers and bullet fragments in or near certain structures in their body. Our standard MRI safety screening will be performed on all subjects.

• If a subject has metal in their body that requires an additional x-ray beyond what is needed for the clinical MRI examination to safely perform the research MRI examination that subject would be excluded.Subjects not being able to return for a follow-up examination

Adults with brain tumors who have had a brain MRI ordered.